Thema: US76243J1051
RYTM, US76243J1051
money-2724245_1920.jpg - Foto: THN
Rhythm Pharmaceuticals stock: IMCIVREE growth drives Q3 update
Rhythm Pharmaceuticals stock is in focus after strong third-quarter IMCIVREE growth. Management also outlined milestones for its next-generation pipeline.
ad-hoc-news.de, heute 00:09 Uhr
RYTM, US76243J1051
Guggenheim keeps USD 143 target for Rhythm Pharmaceuticals ...
Q2 revenue hit USD 71.26 million, up 46.90 percent. Rhythm Pharmaceuticals stock costs EUR 80.25 on October 20, 2026, up 2.49 percent on Nasdaq.
ad-hoc-news.de, 20.10.26 19:16 Uhr
RYTM, US76243J1051
JPMorgan cuts target to USD 145.00 for Rhythm Pharmaceuticals ...
RBC set a USD 159.00 target on October 8, 2026. Rhythm Pharmaceuticals stock costs USD 86.17 on October 16, 2026, down 2.05 percent on Nasdaq.
ad-hoc-news.de, 17.10.26 19:17 Uhr
RYTM, US76243J1051
JPMorgan cuts target for Rhythm Pharmaceuticals stock to ...
Second-quarter revenue reached USD 71.26 million. Rhythm Pharmaceuticals stock costs EUR 79.00 on October 15, 2026, up 2.35 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 21:14 Uhr
RYTM, US76243J1051
RBC raises target for Rhythm Pharmaceuticals stock to USD ...
RBC kept Outperform with a USD 159.00 target on October 8, 2026. Rhythm Pharmaceuticals stock costs EUR 80.50 on October 8, 2026 after EUR 78.75.
ad-hoc-news.de, 08.10.26 20:32 Uhr
Pivotal, Quarter
A Pivotal Quarter Awaits Rhythm Pharmaceuticals
